PIK3CA and breast cancer: Following the paradigm of other common BC biomarkers (i.e. ER, PR, HER2, PD-L1) and their discordance over time [40–42], the magnitude of discordance on PIK3CA mutational status between primary and metastatic lesions could have important clinical implications.